Back to top
more

Moderna (MRNA)

(Real Time Quote from BATS)

$121.13 USD

121.13
1,245,448

-4.01 (-3.20%)

Updated Jul 17, 2024 01:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novavax (NVAX) Commences COVID-19 Vaccine Booster Study

by Zacks Equity Research

Novavax (NVAX) initiates a phase III study to evaluate the booster dose of its COVID vaccine. WHO recommends administering the company's COVID vaccine booster to immunocompromised persons.

Novavax (NVAX) COVID Vaccine Gets EU Nod, 2nd Listing by WHO

by Zacks Equity Research

Novavax (NVAX) secures approval for its COVID vaccine in the European Union. Following EU approval, WHO grants second emergency use listing to the company's COVID vaccine.

Moderna (MRNA) COVID-19 Booster Jab Effective Against Omicron

by Zacks Equity Research

Data from a pseudovirus study demonstrated that the authorized booster dose of Moderna's (MRNA) COVID-19 vaccine significantly increases neutralizing antibody levels against the Omicron variant.

Stock Market News for Dec 21, 2021

by Zacks Equity Research

Benchmarks recorded a steep decline on Monday as investors worried about the fast-spreading omicron variant of COVID-19, raising doubts on the global economic outlook.

Sweta Killa headshot

Biotech ETFs That Outperformed Last Week

by Sweta Killa

Biotech ETFs was the biggest gainer last week.

Emergent (EBS) Begins Dosing in Study on Influenza Vaccine

by Zacks Equity Research

Emergent (EBS) initiates a phase I study evaluating EBS-UFV-001, the company's investigational universal influenza vaccine candidate.

Indrajit Bandyopadhyay headshot

U.S. CDC Recommends mRNA COVID-19 Vaccines Over J&J's Jab

by Indrajit Bandyopadhyay

The U.S. Centers for Disease Control and Prevention prefers the use of PFE, BNTX and MRNA's mRNA-based COVID-19 vaccines instead of J&J's adenovirus-based vaccine due to higher risks of side effects.

J&J's (JNJ) COVID-19 Booster Jab Gets CHMP Recommendation

by Zacks Equity Research

The CHMP recommends the use of the booster dose of J&J's (JNJ) COVID-19 vaccine in adults in Europe. The booster jab already enjoys authorization in the United States and from the WHO for use in adults.

Biotech Stock Roundup: BMY Increases Dividend, MRNA's Study Results & More

by Zacks Equity Research

Moderna's (MRNA) vaccine study results and other pipeline updates have been the biotech sector???s few key highlights during the past week.

The Zacks Analyst Blog Highlights: Pfizer, BNTX, Moderna, and J&J

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, BNTX, Moderna, and J&J

Moderna's (MRNA) Flu Vaccine Data Fails to Impress Investors

by Zacks Equity Research

Moderna's (MRNA) early-stage flu vaccine data seems promising but it fails to meet investors' expectations.

Pfizer, BioNTech Booster Gets FDA Nod for 16- & 17-Year Olds

by Zacks Equity Research

FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for 16- and 17-year olds.

J&J's (JNJ) COVID-19 Booster Jab Gets WHO Recommendation

by Zacks Equity Research

An advisory group of the World Health Organization recommends the booster dose of J&J's (JNJ) COVID-19 vaccine for use in adults.

Pfizer (PFE) COVID-19 Booster Gives Protection Against Omicron

by Zacks Equity Research

Pfizer (PFE) and BioNTech announce lab test data that demonstrates that the three doses of their COVID-19 vaccine provide significant protection against the Omicron variant.

Markets Upbeat on Vaccine Efficacy Against Omicron Variant

by Zacks Equity Research

Markets Upbeat on Vaccine Efficacy Against Omicron Variant

Mark Vickery headshot

Remedies for Omicron Apparent, Markets Up Again

by Mark Vickery

New forms of Covid-19 appear to be growing more highly infectious, if not necessarily more life-threatening.

Kinjel Shah headshot

Vaccine Stocks Down as Omicron May Not Be Too Severe

by Kinjel Shah

Stocks of Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) and Pfizer (PFE) decline as data suggests that Omicron variant may cause less severe cases of COVID-19.

The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, J&J and Regeneron

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, J&J and Regeneron

Sweta Jaiswal, FRM headshot

5 Defensive ETF Bets as Omicron Enters the United States

by Sweta Jaiswal, FRM

Let's look at some safe ETF plays that investors can consider keeping in mind the rising concerns emanating from the new omicron variant.

Novavax (NVAX) Starts Developing Omicron-Specific COVID Jab

by Zacks Equity Research

Novavax (NVAX) begins evaluating its COVID-19 vaccine against the Omicron variant. The company also starts developing an Omicron-specific COVID-19 vaccine.

Kinjel Shah headshot

COVID-19 Vaccine & Drug Makers Gear Up to Fight Omicron

by Kinjel Shah

The Omicron variant ignites fears that currently available COVID-19 vaccines and treatments could be less effective against it. MRNA, PFE, BNTX, REGN and JNJ are some of the industry players gearing up to fight against this new variant.

Sweta Jaiswal, FRM headshot

Bet on Quality ETFs to Combat Omicron and Fed Worries

by Sweta Jaiswal, FRM

Here we highlight some Quality ETFs that can be promising bets amid the current market conditions.

Sanghamitra Saha headshot

Top ETF Stories of November

by Sanghamitra Saha

The emergence of the Omicron variant of Covid-19 and inflationary pressure were key highlights of the broader market in November.

Moderna's (MRNA) Stock Falls on Omicron Variant Concerns

by Zacks Equity Research

Moderna (MRNA) shares decline following a two-day rise as the Omicron-variant creates uncertainty with limited data. The next couple of weeks may provide a clearer picture.

Stock Market News for Dec 1, 2021

by Zacks Equity Research

Benchmarks closed sharply lower on Tuesday after Federal Reserve Chairman Jerome Powell proposed US lawmakers consider asset purchases quicker than planned given the present economic scenario.